Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Despite tremendous efforts in the search for safe, efficacious and non-addictive opioids for pain treatment, morphine remains the most valuable painkiller in contemporary medicine. Opioids exert their pharmacological actions through three opioid-receptor classes, mu, delta and kappa, whose genes have been cloned. Genetic approaches are now available to delineate the contribution of each receptor in opioid function in vivo. Here we disrupt the mu-opioid-receptor gene in mice by homologous recombination and find that there are no overt behavioural abnormalities or major compensatory changes within the opioid system in these animals. Investigation of the behavioural effects of morphine reveals that a lack of mu receptors abolishes the analgesic effect of morphine, as well as place-preference activity and physical dependence. We observed no behavioural responses related to delta- or kappa-receptor activation with morphine, although these receptors are present and bind opioid ligands. We conclude that the mu-opioid-receptor gene product is the molecular target of morphine in vivo and that it is a mandatory component of the opioid system for morphine action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, in animal models, dopamine D1 receptor knockout rats will not self-administer cocaine37 and μ opioid receptor knockout mice will not show the rewarding effects of opioids.153”
From Neurobiology of addiction: a neurocircuitry analysis (2016) · cites this paper as [153]
In the citing paper
“Mice that lack the MOR gene do not develop place preferences or withdrawal symptoms in response to morphine (Matthes et al 1996).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Matthes et al 1996
Citations
Cites
Kieffer, B. L., Befort, K., Gaveriaux-Ruff, C., & Hirth, C. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12048 · Cited by 1,010
Self-citationNeutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology.
Roques, B. P., Noble, F., Daugé, V, Fournié-Zaluski, M. C., & Beaumont, A. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00449-1 · Cited by 756
Self-citationLufkin, T., Dierich, A., LeMeur, M., Mark, M., & Chambon, P. (1991) · Cell · doi:10.1016/0092-8674(91)90034-v · Cited by 697
Self-citationChiara, G. D., & Alan North, R. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90062-b · Cited by 543
Terwilliger, R. Z., Beitner-Johnson, D., Sevarino, K. A., Crain, S. M., & Nestler, E. J. (1991) · Brain Research · doi:10.1016/0006-8993(91)91111-d · Cited by 535
A brief history of opiates, opioid peptides, and opioid receptors.
Brownstein, M. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5391 · Cited by 491
Multiple opioid receptors: ligand selectivity profiles and binding site signatures.
Goldstein, A., & Naidu, A. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09190-4 · Cited by 445
Kieffer, B. L. (1995) · Cellular and Molecular Neurobiology · doi:10.1007/bf02071128 · Cited by 389
Self-citationReduction of Morphine Abstinence in Mice with a Mutation in the Gene Encoding CREB
Maldonado, R., Blendy, J. A., Tzavara, E., Gass, P., Roques, B. P., Hanoune, J., & Schütz, G. (1996) · Science · doi:10.1126/science.273.5275.657 · Cited by 292
Self-citationThe mouse Pgk-1 gene promoter contains an upstream activator sequence
McBurney, M. W., Sutherland, L. C., Adra, C. N., Leclair, B., Rudnicki, M. A., & Jardine, K. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.20.5755 · Cited by 193
Research works printed but not linked: 9
- Goldstein, A. & Naidu, A. Mol. Pharmacol. 36, 265–272 (1989).
- Pasternak, G. W. Clin. Pharmacol. 16, 1–18 (1993).
- Cowan, A. in Handbook of Experimental Pharmacology Opioids II (ed. Herz, A.) Vol. 104, 393–414 (Springer, Berlin, 1993).
- Roques, B. P., Noble, F., Daugé, V., Fournié-Zaluski, M.-C. & Beaumont, A. Pharmacol. Rev. 45, 87–146 (1993).
- Baamonde, A., Daugé, V., Gacel, C. & Roques, B. P. J. Pharmacol. Exp. Ther. 257, 767–773 (1991).
- Koob, G. F. Trends Biochem. Sci. 13, 177–184 (1992).
- Wei, E. T. J. Pharmacol. Exp. Ther. 216, 12–18 (1981).
- Cowan, A., Zhu, X. Z., Mosberg, H. I., Omnaas, J. R. & Porreca, F. J. Pharmacol. Exp. Ther. 246, 950–955 (1988).
- Kitchen, I. et al. J. Pharmacol. Exp. Ther. 275, 1595–1607 (1995).
Cited by
Items 901–1,000 of 1,002
Garrison, A. T., Orsi, D. L., Capstick, R. A., Whomble, D. L., Li, J., Carter, T. R., Felts, A. S., Vinson, P. N., Rodriguez, A. L., Han, A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00192 · Cited by 21
Sleep Deficiency and Opioid Use Disorder
Langstengel, J., & Yaggi, H. K. (2022) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.05.001 · Cited by 26
Ptchd1 mediates opioid tolerance via cholesterol-dependent effects on μ-opioid receptor trafficking
Maza, N. A., Wang, D., Kowalski, C. W., Stoveken, H. M., Dao, M. T., Sial, O. K., Giles, A. C., Grill, B. J., & Martemyanov, K. A. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01135-0 · Cited by 24
Contet, C., Kim, A., Le, D., Iyengar, S. K., Kotzebue, R. W., Yuan, C. J., Kieffer, B. L., & Mandyam, C. D. (2013) · Addiction Biology · doi:10.1111/adb.12040 · Cited by 24
“MOR KO mice were generated by homologous recombination (Matthes et al. 1996) and fully backcrossed on C57BL/6J background.”
MethodSelf-citationPetko, J., Justice-Bitner, S., Jin, J., Wong, V., Kittanakom, S., Ferraro, T. N., Štagljar, I., & Levenson, R. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067608 · Cited by 25
“Knockout mouse experiments have shown that MOR is the primary mediator of the analgesic and rewarding properties of opioid drugs [1].”
BackgroundMethadone Reverses Analgesic Tolerance Induced by Morphine Pretreatment
Posa, L., Accarie, A., Noble, F., & Marie, N. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv108 · Cited by 24
Pujol, C., Pellissier, L. P., Clément, C., Becker, J. A. J., & Merrer, J. L. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0247-y · Cited by 22
Negrete‐Díaz, J. V., Shumilov, K., Real, M. A., Medina-Luque, J., Valderrama‐Carvajal, A., Flores, G., Moreno, A. R., & Rivera, A. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.01.024 · Cited by 25
Greenwell, T. N., Zangen, A., Martin‐Schild, S., Wise, R. A., & Zadina, J. E. (2002) · The Journal of Comparative Neurology · doi:10.1002/cne.10464 · Cited by 28
“The rewarding effects of morphine are eliminated in MOR knockout mice (Matthes et al., 1996) and are unaffected by delta receptor antagonists (Shippenberg et al., 1987), indicating a central role of the MOR in opioid reward.”
BackgroundEndomorphins delay constitutive apoptosis and alter the innate host defense functions of neutrophils
Azuma, Y., Ohura, K., Wang, P., & Shinohara, M. (2002) · Immunology Letters · doi:10.1016/s0165-2478(01)00335-2 · Cited by 24
Catheline, G., Guen, S. L., & Besson, J. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01207-x · Cited by 24
Szumlinski, K. K., Lominac, K. D., Frys, K. A., & Middaugh, L. D. (2004) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2004.00111.x · Cited by 26
“…(2) with a few exceptions (Bohn et al. 2003; Drouin et al. 2002; Sora et al. 2001) the majority of studies have employed mice with congenic B6 (e.g. Becker et al. 2000; Elmer et al. 2002; Hall et al. 2003; Maldonado et al. 1997; Matthes et al. 1996) or congenic MF1 (Gadd et al. 2003) backgrounds.”
BackgroundGaibelet, G., Capeyrou, R., Dietrich, G., & Emorine, L. J. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00407-9 · Cited by 24
Tejwani, G. A., Sheu, M., Sribanditmongkol, P., & Satyapriya, A. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00416-8 · Cited by 24
New Directions in Pain Research: Molecules to Maladies
Levine, J. D. (1998) · Neuron · doi:10.1016/s0896-6273(00)81005-3 · Cited by 24
The 5‐HT3B subunit affects high‐potency inhibition of 5‐HT3receptors by morphine
Baptista‐Hon, D. T., Deeb, T. Z., Othman, N. A., Sharp, D., & Hales, T. G. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01582.x · Cited by 25
“Neuronal m-opioid receptors in the brain mediate the hedonic actions of morphine (Matthes et al., 1996).”
BackgroundWang, B., Wang, L., Wu, B., Guo, R., Zhang, L., Zhang, J., Wang, Z., Wu, F., Feng, Y. Y., Liu, H., et al. (2023) · Anesthesiology · doi:10.1097/aln.0000000000004858 · Cited by 23
“50 MOR is indeed widely distributed in both the central nervous system and the peripheral nervous system.”
BackgroundLaux‐Biehlmann, A., Muller, A. H., Miehe, M., Dirrig‐Grosch, S., Deloulme, J., Delalande, F., Stuber, D., Ciocca, D., DORSSELAER, A. V., Poisbeau, P., et al. (2011) · The Journal of Comparative Neurology · doi:10.1002/cne.22633 · Cited by 26
“…interneurons by acting on the MORs present on these neurons, leading to an increase in the discharge amplitude of pyramidal neurons in the CA1 zone (Miller and Lupica, 1997), and morphine also modifies the efficiency of glutamatergic synapses by acting on the expression of proteins of the…”
BackgroundMorphine‐6‐glucuronide‐Induced Locomotor Stimulation in Mice: Role of Opioid Receptors
Grung, M., Skurtvcit, S., Aasmundstad, T. A., Handal, M., Alkana, R. L., & Mørland, J. G. (1998) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1998.tb01390.x · Cited by 23
García‐Pérez, D., López-Bellido, R., Rodríguez, R. E., Laorden, M. L., Núñez, C., & Milanés, M. V. (2014) · Brain Structure and Function · doi:10.1007/s00429-014-0761-5 · Cited by 26
“On the other hand, l-opioid receptors (MOR) in the VTA are pivotally involved in addictive behaviour (Matthes et al. 1996).”
BackgroundLocalization of endogenous morphine‐like compounds in the mouse spinal cord
Laux‐Biehlmann, A., Delalande, F., Mouheiche, J., Stuber, D., DORSSELAER, A. V., Bianchi, E., Bézard, E., Poisbeau, P., & Goumon, Y. (2012) · The Journal of Comparative Neurology · doi:10.1002/cne.22811 · Cited by 24
“Morphine and its derivative, M6G, preferentially bind the MOR and the d opioid receptor (DOR; Matthes et al., 1996; Trescot et al., 2008).”
BackgroundA Subanalgesic Dose of Morphine Eliminates Nalbuphine Anti-Analgesia in Postoperative Pain
Gear, R. W., Gordon, N. C., Hossaini-Zadeh, M., Lee, J. S., Miaskowski, C. A., Paul, S. M., & Levine, J. D. (2008) · Journal of Pain · doi:10.1016/j.jpain.2007.11.011 · Cited by 23
Bonnard, E., Poras, H., Nadal, X., Maldonado, R. J., Fournié‐Zaluski, M., & Roques, B. P. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.116 · Cited by 33
“This is in consistent with the genetic evidence for the involvement of only mu opioid receptor (MOR) in the early phase and both MOR and delta opioid receptor (DOR) in the late phase (Matthes et al. 1996; Martin et al. 2003; Gav eriaux-Ruff et al. 2008) and the higher affinity of ENKs for DOR than for MOR (Dhawan et a…”
Self-citationVathy, I., Šlamberová, R., & Liu, X. (2007) · Developmental Psychobiology · doi:10.1002/dev.20240 · Cited by 22
“It is well documented that morphine induces its rewarding effects through its action on the m-opioid receptor (Hall et al., 2003; Matthes et al., 1996).”
BackgroundGenetic dissociation of morphine analgesia from hyperalgesia in mice
Marrone, G. F., Rouzic, V. L., Váradi, A., Xu, J., Rajadhyaksha, A. M., Majumdar, S., Pan, Y., & Pasternak, G. W. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4600-2 · Cited by 23
“…1994; Uhl et al. 1994) and knockout approaches established the importance of the 7TM variants in morphine analgesia (Charbogne et al. 2014; Corder et al. 2017; Kitanaka et al. 1998; Loh et al. 1998; Matthes et al. 1996; Schuller et al. 1999; Sora et al. 2001; Sora et al. 1997; Tian et al. 1997).”
BackgroundLi, J., Wei, Z., Zhang, J., Hakonarson, H. H., & Cook‐Sather, S. D. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0074-4 · Cited by 24
Welters, I. D. (2003) · Der Anaesthesist · doi:10.1007/s00101-003-0506-y · Cited by 23
Opioid Receptor Trafficking and Signaling: What Happens After Opioid Receptor Activation?
Bian, J., Wu, N., Su, R., & Li, J. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9755-5 · Cited by 32
Xu, X. S., Etropolski, M. S., Upmalis, D. H., Okamoto, A., Lin, R., & Nandy, P. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0786-5 · Cited by 23
Ide, S., Minami, M., Ishihara, K., Uhl, G. R., Satoh, M., Sora, I., & Ikeda, K. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.03.008 · Cited by 28
“These observations are especially interesting because the distributions of DOP and KOP are not apparently altered in MOP-KO mice (Loh et al., 1998; Matthes et al., 1996; Sora et al., 1997b).”
BackgroundSánchez‐Blázquez, P., Rodríguez‐Díaz, M., DeAntonio, I., & Garzón, J. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35065-7 · Cited by 23
Guen, S. L., Gestreau, C., & Besson, J. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02678.x · Cited by 27
“Our results also corroborate the findings made in knock-out mice with deleted MOR, in which no sign of naloxone-precipitatedMWwas observed (Matthes et al., 1996; Childers, 1997; Sora et al., 2001).”
Marquez, P. V., Baliram, R., Gajawada, N., Friedman, T. C., & Lutfy, K. (2006) · Behavioral Neuroscience · doi:10.1037/0735-7044.120.1.10 · Cited by 25
“Morphine has been shown to produce antinociception, reward and motor stimulation via activation of the mu opioid receptors, because these actions of the drug were absent in mice lacking mu opioid receptors (Matthes et al., 1996).”
BackgroundPark, Y., Ma, T., Tanaka, S., Jang, C., Loh, H. H., Ko, K. H., & Ho, I. K. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(00)00265-3 · Cited by 23
Epidural ketamine potentiates epidural morphine but not fentanyl in acute nociception in rats
Hoffmann, V. L. H., Baker, A. K., VERCAUTEREN, M. P., Adriaensen, H. F., & Meert, T. F. (2003) · European Journal of Pain · doi:10.1016/s1090-3801(02)00074-5 · Cited by 26
“Although both fentanyl and morphine have been demonstrated to bind with varying degree to l, o, and j receptors, Matthes et al. have shown that the antinociceptive properties of morphine are mediated by l receptor activation and not by j or o receptor activation (Matthes et al., 1996).”
BackgroundSchmidt, P. M., Schmolke, C., Mußhoff, F., Prohaska, C., Menzen, M., & Madea, B. (2001) · Forensic Science International · doi:10.1016/s0379-0738(00)00333-9 · Cited by 23
Structural Determinants for the Binding of Morphinan Agonists to the μ-Opioid Receptor
Cong, X., Campomanes, P., Kless, A., Schapitz, I., Wagener, M., Koch, T., & Carloni, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135998 · Cited by 22
“Both beneficial and adverse pharmacodynamic effects of classical morphine-like drugs are attributable to the activation of μORs [11].”
BackgroundHistamine, histamine H3 receptor, and alcohol use disorder
Panula, P. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14634 · Cited by 22
“Among the most studied receptor are the opioid receptors (Contet, Kieffer, & Befort, 2004; Matthes et al., 1996), dopamine D1 and D2 receptors (Cunningham et al., 2000; El‐Ghundi et al., 1998), 5‐HT receptors (Crabbe et al., 1996; de Bruin et al., 2013),metabotropic glutamate receptors (Zhou et…”
BackgroundTherapeutic potential of opioid receptor heteromers in chronic pain and associated comorbidities
Gaborit, M., & Massotte, D. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15772 · Cited by 25
“Studies using mice deficient in the μ opioid receptor revealed that this receptor is the primary molecular target of opioids, mediating both analgesic and unwanted side effects (Matthes et al., 1996).”
BackgroundThe chronological evolution of fluorescent GPCR probes for bioimaging
Wu, Y., Zhang, B., Xu, H., He, M., Deng, X., Zhang, L., Dang, Q., Fan, J., Guan, Y., Peng, X., et al. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215040 · Cited by 22
Pryce, K. D., Serafini, R. A., Ramakrishnan, A., Nicolais, A., Giosan, I. M., Polizu, C., Torres‐Berrío, A., Vuppala, S., Kronman, H. G., Ruiz, A., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01350-3 · Cited by 23
Bingel, U. (2010) · Der Schmerz · doi:10.1007/s00482-010-0901-7 · Cited by 30
Wang, D., Chen, T., Zhou, X., Couture, R., & Hong, Y. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.08.069 · Cited by 23
“Morphine produces analgesia via MORs because morphine fails to induce analgesia in mice lacking the MOR gene (Matthes et al., 1996).”
Evolving Knowledge of Opioid Genetics in Cancer Pain
Droney, J., Riley, J. L., & Ross, J. R. (2011) · Clinical Oncology · doi:10.1016/j.clon.2011.04.015 · Cited by 22
“MOR knockoutmice (in which the MOR gene has been ‘turned off’) are entirely refractory to the analgesic effects of morphine [20e22] and do not experience any side-effects from morphine [21,23].”
BackgroundJones, J. D., Luba, R. R., Vogelman, J., & Comer, S. D. (2015) · American Journal on Addictions · doi:10.1111/ajad.12316 · Cited by 24
“The mu subtype of opioid receptors is thought to primarily mediate opioid analgesia, reward and withdrawal (21, 22).”
BackgroundKnapman, A., & Connor, M. A. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12644 · Cited by 22
“Clinically important opioid analgesics act by binding to the μ-opioid receptor (Matthes et al., 1996; Alexander et al., 2013a), making this receptor a prime candidate for contributing to the genetic component of inter-individual differences in opioid response.”
BackgroundGlass, M. J. (2010) · Vitamins and hormones · doi:10.1016/s0083-6729(10)82008-4 · Cited by 24
“After providing some important background information, this paper describes recent results characterizing the synaptic organization and functional interactions of NMDA and ORs in the CeA, particularly with respect to opioid withdrawal.”
InfluentialCastañé, A., Wells, L. A., Sòria, G., Hourani, S. M. O., Ledent, C. A., Kitchen, I., Opacka‐Juffry, J., Maldonado, R. J., & Valverde, O. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.299 · Cited by 22
“The apparatus consisted of two main square conditioning compartments (15 15 15 cm), with differences in texture and colours, separated by a triangular central area (Matthes et al., 1996).”
BackgroundSelf-citationEndogenous morphine modulates acute thermonociception in mice
Guarna, M., Bianchi, E., Bartolini, A., Ghelardini, C., Galeotti, N., Bracci, L., Neri, C., Sonetti, D., & Stefano, G. B. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00708.x · Cited by 27
Guo, L., Aschenbach, L. C., He, H., Selley, D. E., & Zhang, Y. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.093 · Cited by 24
Rational treatment of addiction
Terenius, L. Y. (1998) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(98)80132-4 · Cited by 22
Mizoguchi, H., Tseng, L. F., Suzuki, T., Sora, I., & Narita, M. (2002) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.89.229 · Cited by 22
Andraka, E., Phillips, R. A., Brida, K. L., & Day, J. J. (2024) · Addiction Neuroscience · doi:10.1016/j.addicn.2024.100153 · Cited by 23
“For example, morphine conditioned place preference and dependence is lost in transgenic mice with constitutive deletion of the Oprm1 gene [1], demonstrating that this receptor is required for opioid reward.”
Kwok, C. H. T., Harding, E. K., Burma, N. E., Markovic, T., Massaly, N., van den Hoogen, N. J., Stokes-Heck, S., Gambeta, E., Komarek, K., Yoon, H. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50657-7 · Cited by 26
“C) 15 – 17 .”
Delta Opioid Receptor Agonists Ameliorate Colonic Inflammation by Modulating Immune Responses
Nagata, K., Nagase, H., Okuzumi, A., & Nishiyama, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730706 · Cited by 22
“However, the effects of KNT-127 on peripheral tissues other than the CNS have not been clarified.”
BackgroundInfluentialEckert, D. J., & Yaggi, H. K. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202108-2014ci · Cited by 27
Zhang, Y., Wang, Z., Cox, D. P., & Civelli, O. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0627-7 · Cited by 22
Shigeta, Y., Kasai, S., Han, W., Hata, H., Nishi, A., Takamatsu, Y., Hagino, Y., Yamamoto, H., Koide, T., Shiroishi, T., et al. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32830d0b9e · Cited by 21
Diatchenko, L. B., Robinson, J. E., & Maixner, W. D. (2011) · European Journal of Pain Supplements · doi:10.1016/j.eujps.2011.08.022 · Cited by 21
“MOR1 is the primary target of both endogenous and exogenous opioid analgesics, which mediates basal nociception as well as μ-opioid receptor agonists responses(Matthes et al,1996; Sora et al, 1997;Uhl et al,1999;Edwards et al,2006).”
Galeote, L., Maldonado, R. J., & Berrendero, F. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05247.x · Cited by 22
“While MOP-r mediates the rewarding properties of drugs of abuse (Matthes et al. 1996; Roberts et al. 2000; Berrendero et al. 2002; Ghozland et al. 2002), KOP-r regulates dysphoric and aversive effects (Simonin et al. 1998; Mendizabal et al. 2006), and can counteract the nociceptive responses…”
Self-citationNagai, J., Kurokawa, M., Takeshima, H., Kieffer, B. L., & Ueda, H. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.115121 · Cited by 21
“It is fortunate to show that KUROBOX analysis using MOP / mice reveals the phenotype of hypolocomotion, as reported previously (Matthes et al., 1996; Tian et al., 1997).”
MethodSelf-citationKao, J., Chen, S., Ma, H. I., Law, P., Tao, P., & Loh, H. H. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.165399 · Cited by 21
“739 In the MOR( / ) mice, the rewarding responses to morphine were not observed (Matthes et al., 1996).”
BackgroundIde, S., Minami, M., Uhl, G. R., Satoh, M., Sora, I., & Ikeda, K. (2011) · Molecular Pain · doi:10.1186/1744-8069-7-23 · Cited by 24
“Developing mice that lack the MOP receptor gene has made possible the discovery of the molecular mechanisms that underlie the effects of opioids [6-9].”
BackgroundMu and delta opioid receptors play opposite nociceptive and behavioural roles on nerve‐injured mice
Martínez‐Navarro, M., Cabañero, D., Wawrzczak‐Bargieła, A., Robé, A., Gavériaux‐Ruff, C., Kieffer, B. L., Przewłocki, R., Baños, J.-E., & Maldonado, R. J. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14911 · Cited by 25
“…areas in the regulation of thermal sensitivity by opioids has been previously described in different models using male mice and rats (Bousselmame, Eustache, MichaelTitus, & Costentin, 1991; Chen, Cheng, Sun, & Shyu, 2008; McGaraughty & Heinricher, 2002; Van Amsterdam & Llorens-Cortes, 1988).”
MethodSelf-citationRecent advances in the use of opioids for cancer pain
Droney, J. (2009) · Journal of Pain Research · doi:10.2147/jpr.s6905 · Cited by 21
Ansonoff, M. A., Portoghese, P. S., & Pintar, J. E. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1826-7 · Cited by 21
“Most opiate analgesics currently in clinical use are thought to exert their biological effects through activation of the μ opioid receptor (MOR) ( Matthes et al. 1996; Oertel and Lotsch 2008; Roy et al. 1998a, b; Schuller et al. 1999; Sora et al. 1997; Trescot et al. 2008), while analgesics with selectivity for the δ…”
BackgroundObeng, S., Yuan, Y., Jali, A. M., Selley, D. E., & Zhang, Y. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.013 · Cited by 21
“Moreover, studies using MOR knock-out mice have shown that the dependence and abuse liability, respiratory depression, and constipation associated with opioids were abolished, indicating that the addiction and abuse liability of opioids are mainly mediated through the MOR (GavériauxRuff and Kieffer, 2002; Matthes et a…”
BackgroundMizoguchi, H., Wu, H.-E., Narita, M., Sora, I., Hall, F. S., Uhl, G. R., Loh, H. H., Nagase, H., & Tseng, L. F. (2003) · Journal of Pharmacological Sciences · doi:10.1254/jphs.93.423 · Cited by 21
Mammalian G-protein function in vivo: New insights through altered gene expression
Offermanns, S. (2006) · Springer eBooks · doi:10.1007/bfb0035551 · Cited by 24
Narita, M., Ozaki, S., & Suzuki, T. (2002) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.89.224 · Cited by 21
McMahon, B. M., Stewart, J. A., Jackson, J. G., Fauq, A. H., McCormick, D., & Richelson, E. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02511-2 · Cited by 21
Friderichs, E., Christoph, T., & Buschmann, H. (2007) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.a02_269.pub2 · Cited by 21
Central control of opioid-induced mechanical hypersensitivity and tolerance in mice
Yin, G., Duan, K., Dong, D., Du, F., Guo, C., Zhang, C., Liu, X., Sun, Y., Huang, T., Cui, G.-F., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.09.014 · Cited by 24
Talagayev, V., Chen, Y., Doering, N. P., Obendorf, L., Denzinger, K., Puls, K., Lam, K., Liu, S., Wolf, C. A., Noonan, T., et al. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c02158 · Cited by 26
Alijanpour, S., Tirgar, F., & Zarrindast, M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.11.023 · Cited by 19
From Pharmacology to Physiology: Endocrine Functions of μ-Opioid Receptor Networks
Jaschke, N., Pählig, S., Pan, Y., Hofbauer, L. C., Göbel, A., & Rachner, T. D. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.02.004 · Cited by 24
The mu opioid receptor and the orphan receptor GPR151 contribute to social reward in the habenula
Allain, F., Carter, M., Dumas, S., Darcq, E., & Kieffer, B. L. (2022) · Scientific Reports · doi:10.1038/s41598-022-24395-z · Cited by 23
Self-citationMuller, I., Sarramégna, V., Renault, M., Lafaquière, V., Sébaï, S. C., Milon, A., & Talmont, F. (2008) · The Journal of Membrane Biology · doi:10.1007/s00232-008-9112-x · Cited by 20
“The human muopioid receptor (HuMOR) is the unique receptor for the alkaloid drug extracted from opium poppy, namely, morphine, and for its diacetylated form, heroin, and is therefore responsible for drug addiction ( Matthes et al. 1996 ).”
BackgroundChen, S., Ma, H.-I., Han, J.-M., Lu, R., Tao, P., Law, P., & Loh, H. H. (2010) · Journal of Biomedical Science · doi:10.1186/1423-0127-17-28 · Cited by 20
“Previous studies also reported that morphine at doses up to 56 mg/kg did not show significant antinociceptive effect in homozygous MOR-KO mice [11,12,5].”
BackgroundRole of HIV-1 Infection in Addictive Behavior: A Study of a HIV-1 Transgenic Rat Model
Chang, S. L., & Vigorito, M. (2006) · American Journal of Infectious Diseases · doi:10.3844/ajidsp.2006.98.106 · Cited by 19
Tchalova, K., Sadikaj, G., Moskowitz, D. S., Zuroff, D. C., & Bartz, J. A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0600-4 · Cited by 23
Li, X.-Y., Sun, L. J., He, J., Chen, Z.-L., Zhou, F., Liu, X.-Y., & Liu, R.-S. (2010) · Brain Research · doi:10.1016/j.brainres.2010.02.070 · Cited by 24
“Previous studies of morphine tolerance focused on the mu-opioid receptor (MOR), since morphine is primarily an MOR agonist (Matthes et al., 1996; Simonin et al., 1998; Zhu et al., 1999).”
Sadeghi, M., Tzschentke, T., & Christie, M. J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12566 · Cited by 20
“It is well established that the μ receptor mediates both analgesic activity and adverse effects of μ receptor agonists (Matthes et al., 1996).”
Transcriptional Modulation of Mouse μ-Opioid Receptor Distal Promoter Activity by Sox18
Im, H., Smirnov, D., Yuhi, T., Raghavan, S., Olsson Jane, E., Muscat, G. E. O., Koopman, P. A., & Loh, H. H. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.6.1486 · Cited by 21
Pei, G., Ling, K., Pu, L., Cunningham, M. D., & Ma, L. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00790-4 · Cited by 20
Post-Transcriptional Regulation of Mouse κ-Opioid Receptor Expression
Wei, L.-N., Hu, X., Bi, J., & Loh, H. H. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23213-2 · Cited by 44
The neural circuits and signalling pathways of opioid use disorder
Mathis, V., Ehrlich, A. T., & Darcq, E. (2025) · Nature reviews. Neuroscience · doi:10.1038/s41583-025-00982-7 · Cited by 25
“Notably, KO mouse models for MORs, DORs and KORs have been instrumental in elucidating the distinct roles of these receptors in opioid pharmacology and have confirmed that MORs primarily mediate opioid-induced analgesia 18,111–113 .”
InfluentialN-methyl-D-aspartate receptors involved in morphine-induced hyperalgesia in sensitized mice
Ahmadi, S., Golbaghi, H., Azizbeigi, R., & Esmailzadeh, N. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.04.048 · Cited by 20
Jiang, X., Li, S., Zhang, H., & Wang, L. (2020) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2020.107405 · Cited by 19
Reduced MC4R signaling alters nociceptive thresholds associated with red hair
Robinson, K. C., Kemény, L. V., Fell, G. L., Hermann, A. L., Allouche, J., Ding, W., Yekkirala, A. S., Hsiao, J. J., Su, M. Y., Theodosakis, N., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd1310 · Cited by 20
Drugs of Abuse—Opioids, Sedatives, Hypnotics
Azevedo, K., Johnson, M., Wassermann, M., & Evans-Wall, J. (2021) · Critical Care Clinics · doi:10.1016/j.ccc.2021.03.003 · Cited by 20
Anti‐nociception mediated by a κ opioid receptor agonist is blocked by a δ receptor agonist
Taylor, A. M. W., Roberts, K. W., Pradhan, A. A. A., Akbari, H., Walwyn, W. M., Lutfy, K., Carroll, F. I., Cahill, C. M., & Evans, C. J. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12810 · Cited by 24
“Male and female MOP KO (exon 2 KO) mice and littermate wild-type (WT) controls (Matthes et al., 1996) were fully backcrossed to the C57Bl/6J line.”
Capone, F. T., Adriani, W., Shumilina, M. V., Izykenova, G. A., Granstrem, O., Dambinova, S. A., & Laviola, G. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1062-y · Cited by 19
“Interestingly, hemizygous mice (expressing nearly 50% of μ receptors, compared to wild-type levels) displayed place conditioning to morphine already at 5 mg/kg, while at least a 10-mg/kg dose was needed in the wild type (Matthes et al. 1996; Sora et al. 2001).”
BackgroundMethodSeip, K. M., Reed, B., Ho, A., & Kreek, M. J. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2380-7 · Cited by 20
“1991; Sinha 2008; Yap and Miczek 2008) or opioid function (Kreek and LaForge 2007; Le Merrer et al. 2009; Matthes et al. 1996; Sim-Selley et al. 2000) may drive specific vulnerabilities to heroin dependence and provides direction to future molecular studies.”
Peng, G., Fan, Z., Wang, X., & Chen, C. (2016) · Journal of Limnology · doi:10.4081/jlimnol.2016.1458 · Cited by 19
“The reason may be that the nitrate needs to be converted to ammonium catalyzed by nitrate reductase (NR) and nitrite reductase (NiR) in the cytosol and chloroplast, respectively, before being incorporated into organic compounds (Matthes et al., 1996).”
BackgroundMu-Opioid Receptors Expressed in Glutamatergic Neurons are Essential for Morphine Withdrawal
Zhang, X., Li, Q., Dong, Y., Yan, W., Song, K., Lin, Y., & Sun, Y.-G. (2020) · Neuroscience Bulletin · doi:10.1007/s12264-020-00515-5 · Cited by 19
TREK1 channel activation as a new analgesic strategy devoid of opioid adverse effects
Busserolles, J., Soussia, I. B., Pouchol, L., Marie, N., Méleine, M., Devilliers, M., Judon, C., Schopp, J., Clémenceau, L., Poupon-Bejuit, L., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15243 · Cited by 22
“…adverse effects (constipation, nausea, vomiting, sedation, respiratory depression,and dependence) of opioids are due to the activation of the same μ opioid receptor whose ubiquitous location is the origin of the wide diversity of the effects of opioids (Marrone et al., 2017; Matthes et al., 1996).”
Oral extended-release oxymorphone: a new choice for chronic pain relief
Matsumoto, A. K. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.10.1515 · Cited by 19
“(2007) 8(10) 1517 seems to be mediated through the δ-opioid receptor [24-26,29].”
BackgroundNovel exonic μ‐opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence
Smith, R. J., Doyle, G. A. R., Han, A. M., Crowley, J. J., Oslin, D. W., Patkar, A. A., Mannelli, P., DeMaria, P. A., O’Brien, C. P., & Berrettini, W. H. (2004) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30105 · Cited by 19
Inui, Y., Azuma, Y., & Ohura, K. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00065-6 · Cited by 20
Metadata
- Authors
- Matthes, H. W. D., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dollé, P., Tzavara, E., Hanoune, J., Roques, B. P., & Kieffer, B. L.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- University of Surrey (GB)
- Institut de génétique et de biologie moléculaire et cellulaire (FR)
- Inserm (FR)
- Venue
- Nature
- Published
- 1996-10
- Volume
- 383
- Issue
- 6603
- Pages
- 819-823
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2051746492
- Cited by
- 1,722
- References
- 25
- Citations by year
- 2026: 36 · 2025: 40 · 2024: 45 · 2023: 52 · 2022: 53 · 2021: 56 · 2020: 59 · 2019: 56 · 2018: 53 · 2017: 43 · 2016: 59 · 2015: 53 · 2014: 60 · 2013: 65 · 2012: 58
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- mu-opioid receptor, morphine, analgesia, opioid reward, place preference, opioid withdrawal, physical dependence, knockout mice, delta opioid receptor, kappa opioid receptor, opioid system, pain management
- MeSH terms
- Analgesics, Animals, Behavior, Animal, Cell Line, Enkephalins, Mice, Inbred C57BL, Morphine, Morphine Dependence, Narcotics, Reward, Substance Withdrawal Syndrome, Gene Deletion, Receptors, Opioid, mu, Receptors, Opioid, delta, Receptors, Opioid, kappa, Mice, Knockout, Enkephalin, Ala(2)-MePhe(4)-Gly(5)-, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.